Q4 Earnings Estimate for TARS Issued By HC Wainwright

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities researchers at HC Wainwright issued their Q4 2025 EPS estimates for Tarsus Pharmaceuticals in a research report issued to clients and investors on Wednesday, February 26th. HC Wainwright analyst O. Livnat anticipates that the company will post earnings per share of ($0.06) for the quarter. HC Wainwright currently has a “Buy” rating and a $73.00 target price on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ FY2028 earnings at $5.10 EPS and FY2029 earnings at $6.29 EPS.

Several other research firms have also recently weighed in on TARS. The Goldman Sachs Group raised their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Oppenheimer upped their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Barclays dropped their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Guggenheim reaffirmed a “buy” rating and set a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $61.33.

Tarsus Pharmaceuticals Trading Up 3.1 %

Shares of TARS stock opened at $42.56 on Thursday. Tarsus Pharmaceuticals has a 52-week low of $20.08 and a 52-week high of $57.28. The business’s fifty day moving average is $51.31 and its 200 day moving average is $43.00. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The company has a market capitalization of $1.63 billion, a PE ratio of -11.17 and a beta of 1.01.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.08. The business had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Toronto Dominion Bank purchased a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $105,714,000. Jennison Associates LLC boosted its position in Tarsus Pharmaceuticals by 47.2% during the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after buying an additional 698,712 shares during the period. Lord Abbett & CO. LLC grew its stake in shares of Tarsus Pharmaceuticals by 115.2% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock valued at $70,873,000 after buying an additional 685,111 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Tarsus Pharmaceuticals by 189.4% in the fourth quarter. Millennium Management LLC now owns 644,010 shares of the company’s stock worth $35,659,000 after buying an additional 421,495 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Tarsus Pharmaceuticals by 2,088.8% in the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock worth $14,477,000 after buying an additional 420,057 shares during the period. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.